Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/30384
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNgian G.-S.en
dc.contributor.authorLittlejohn G.O.en
dc.contributor.authorGuymer E.K.en
dc.date.accessioned2021-05-14T10:16:18Zen
dc.date.available2021-05-14T10:16:18Zen
dc.date.copyright2011en
dc.date.created20110228en
dc.date.issued2012-10-05en
dc.identifier.citationInternational Journal of Rheumatic Diseases. 14 (1) (pp 6-11), 2011. Date of Publication: February 2011.en
dc.identifier.issn1756-1841en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/30384en
dc.description.abstractFibromyalgia syndrome (FMS) is a chronic disorder of widespread pain with high personal and societal burdens. Although targeted pharmacotherapies have become available in recent years, it remains a challenging condition to treat. Despite no randomized controlled trials addressing the short- or long-term use of opioids in FMS, their use remains prevalent. In this article we discuss the role of opioids and other analgesics in the management of FMS, with particular focus on problems associated with their use. We review aspects of the pathophysiology of FMS and consider how specific factors may contribute to the lack of efficacy of opioids in this condition. Finally, we discuss drugs with combined opioid and anti-opioid action and their roles in FMS. There is insufficient evidence to recommend the routine use of opioids in FMS. As well as having a significant adverse effect profile, their inefficacy may be due to their inability to target the pathophysiologic processes involved in this central sensitization syndrome. © 2010 The Authors. International Journal of Rheumatic Diseases © 2010 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd.en
dc.languageEnglishen
dc.languageenen
dc.publisherBlackwell Publishing (550 Swanston Street, Carlton South VIC 3053, Australia)en
dc.titleThe use of opioids in fibromyalgia.en
dc.typeReviewen
dc.type.studyortrialReview article (e.g. literature review, narrative review)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/j.1756-185X.2010.01567.xen
dc.publisher.placeAustraliaen
dc.identifier.pubmedid21303476 [http://www.ncbi.nlm.nih.gov/pubmed/?term=21303476]en
dc.identifier.source361230835en
dc.identifier.institution(Ngian, Guymer, Littlejohn) Rheumatology Department, Monash Medical Centre, Melbourne, VIC, Australiaen
dc.description.addressG.-S. Ngian, Rheumatology Department, Monash Medical Centre, Block E, Level 3, 246 Clayton Rd., Clayton 3168, VIC., Australia. E-mail: gene-siew@excite.comen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2012 Elsevier B.V., All rights reserved.en
dc.subect.keywordsAnalgesics Drug therapy Fibromyalgia Opioids Tramadolen
dc.identifier.authoremailNgian G.-S.; gene-siew@excite.comen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeReview-
crisitem.author.deptRheumatology-
Appears in Collections:Articles
Show simple item record

Page view(s)

16
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.